尤瑞克林治疗急性缺血性脑梗死的疗效

摘要

目的 评价注射用尤瑞克林治疗急性缺血性脑梗死的疗效.方法 选取2011年2月～2012年7月符合条件的127例急性脑梗死患者分为常规治疗组(n=65)和尤瑞克林组(n=62),常规治疗组给予常规治疗,尤瑞克林组在常规治疗基础上加用尤瑞克林治疗,用法为每次将0.15PNA单位尤瑞克林注射液加入到100 mL注射用生理盐水中,1次/d,共治疗2周.对治疗前后神经功能缺损评分(NIHSS)、Bartherl指数进行比较,观察两组疗效.结果 尤瑞克林治疗过程中未发现有药物不良反应或副作用.尤瑞克林组患者治疗前NIHSS评分和Bartherl指数分别为(14.93±5.73)分及(32.39±5.87),治疗后NIHSS评分和Bartherl指数分别为(8.12±4.61)分及(73.28±4.92),差异均有统计学意义(P＜0.05)；治疗后常规治疗组NIHSS评分和Bartherl指数分别为(12.37±3.89)分及(51.78±7.52),与尤瑞克林组相比,差异均有统计学意义(P＜0.05).尤瑞克林组患者治疗有效率为87％,相对常规治疗组(65％)差异有统计学意义(P＜0.05) 结论 尤瑞克林治疗急性脑梗死疗效确切,安全可靠.%Objective To evaluate the clinical effect of Urinary Kallidinogenase in treating acute ischemic cerebral infarction.Methods One hundred and twenty seven qualified patients with acute ischemic cerebral infarction from February 2011 to July 2012 were divided into conventional therapy group and Urinary Kallidinogenase group, respectively treated by conventional therapy and Urinary Kallidinogenase on the basis of former.The dosage of 0.15 PNA U of Urinary Kallidinogenase Injection was added to 100 mL saline, once per day, for two weeks NIHSS score and Bartherl index before and after the treatment were compared, curative effect was observed.Results In Urinary Kallidinogenase group, there was no adverse drug reaction or side effect; the NIHSS score and Bartherl index was respectively (14.93±5.73) points and (32.39±5.87) before treatment, and (8.12±4.61) points and (73.28±4.92) respectively after treatment, with statistically significant differences (P < 0.05).Compared with those of Urinary Kallidinogenase group, the NIHSS score and Bartherl index of conventional therapy group was respectively (12.37±3.89) points and (51.78±7.52) after treatment, with statistically significant differences (P < 0.05).The effective rate of Urinary Kallidinogenase group and conventional therapy group was 87% and 65% respectively, with statistically significant difference (P < 0.05).Conclusion For acute ischemic infarction, Urinary Kallidinogenase has actual effect, which is safe and reliable.